NRX Pharmaceuticals (NRXP) Cost of Revenue (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Cost of Revenue of $631000.0 for Q1 2026, up 54.66% quarter-over-quarter from $408000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Cost of Revenue (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Cost of Revenue for 2 consecutive years, with $631000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Cost of Revenue changed N/A year-over-year to $631000.0; the TTM figure through Mar 2026 stood at $1.1 million (changed N/A YoY), while the FY2025 annual figure was $505000.0, changed N/A from the prior year.
Cost of Revenue grew to $631000.0 in Q1 2026 per NRXP's latest filing, from $408000.0 in the prior quarter.
Across five years, Cost of Revenue topped out at $631000.0 in Q1 2026 and bottomed at $97000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	145.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	93.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	174.53 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	298.26 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	387.98 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	67.21 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00	675,000.00

Download Data